Immune complexes as therapy for autoimmunity.
For several decades, intravenous Ig has been used as treatment for a variety of immune-related diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies, systemic lupus erythematosus, myasthenia gravis, Guillain-Barré syndrome, skin blistering syndromes, and Kawasaki disease. Despite years of use, its mechanism of immunomodulation is still unclear. Recent studies using mouse models of ITP and arthritis, including one reported in this issue of the JCI, now provide some insights into this mechanism and the rationale for the development of Fcgamma receptor-targeted therapeutics.
Clynes
Raphael
R
Department of Medicine and Microbiology, Columbia University, New York, New York 10032, USA. rc645@columbia.edu
D000818:Animals; D000936:Antigen-Antibody Complex / Q000276:immunology*; D015551:Autoimmunity / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology; D007167:Immunotherapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D011961:Receptors, Fc / Q000276:immunology; D018029:Rho(D) Immune Globulin / Q000276:immunology
D000936:Antigen-Antibody Complex; D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc; D018029:Rho(D) Immune Globulin